Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.
Provide a brief overview of the treatment landscape for HER2-low advanced breast cancer. Briefly highlight key insights from pivotal trials that have helped shape this treatment space: